Euroapi (XPAR:EAPI) 3-Year Book Growth Rate: -11.20% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:EAPI Euroapi SA XPAR:EAPI
59 GF Score
Price €1.27
GF Value €2.88
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Euroapi 3-Year Book Growth Rate?

Euroapi XPAR:EAPI -0.93% 59 3-Year Book Growth Rate is -11.20% as of Dec. 2025. GuruFocus rates XPAR:EAPI with a GF Score™ of 59/100 and a GF Value™ of €2.88 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 911 Drug Manufacturers companies, Euroapi ranks worse than 82.66% on this metric.

Euroapi's Book Value per Share for the quarter that ended in Dec. 2025 was €8.28.

During the past 12 months, Euroapi's average Book Value per Share Growth Rate was -19.80% per year. During the past 3 years, the average Book Value per Share Growth Rate was -11.20% per year. During the past 5 years, the average Book Value per Share Growth Rate was -4.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of Euroapi was 2.90% per year. The lowest was -11.20% per year. And the median was -1.95% per year.


Euroapi  (XPAR:EAPI) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.


Euroapi 3-Year Book Growth Rate Related Terms


XPAR:EAPI vs ZTS, UTHR, VTRS: 3-Year Book Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Euroapi's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Euroapi 3-Year Book Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Euroapi's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Euroapi's 3-Year Book Growth Rate falls into.


XPAR:EAPI
59GF Score
Euroapi SA XPAR:EAPI
3-Year Book Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Euroapi 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of -11.20% mean?
Euroapi (XPAR:EAPI) has a 3-Year Book Growth Rate of -11.20% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Euroapi and its competitors. According to the industry distribution chart, Euroapi ranks #753 out of 911 companies in the Drug Manufacturers industry, placing it in the top 82.7%.
Is Euroapi's 3-Year Book Growth Rate too high?
Euroapi's current 3-Year Book Growth Rate is -11.20%. Based on the distribution chart, Euroapi ranks #753 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Euroapi has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Euroapi's 3-Year Book Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euroapi ranks #753 out of 911 companies for 3-Year Book Growth Rate. This places Euroapi in the lower half of its industry. The industry median 3-Year Book Growth Rate is 4.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.80, based on 911 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Euroapi and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euroapi's current 3-Year Book Growth Rate is -11.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroapi stock overvalued right now?
Based on GuruFocus' analysis, Euroapi (XPAR:EAPI) is currently considered Possible Value Trap. The stock's GF Value™ is €2.88, compared to a current price of €1.27 — trading 55.8% below its estimated fair value. The current 3-Year Book Growth Rate is -11.20%. Euroapi's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Euroapi (XPAR:EAPI), the current 3-Year Book Growth Rate is -11.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Euroapi (XPAR:EAPI) Overvalued in 2026?

Based on GuruFocus' analysis, Euroapi stock appears to be undervalued. The current stock price of €1.27 is trading 55.8% below its estimated GF Value™ of €2.88. GuruFocus considers Euroapi to be Possible Value Trap.

Key valuation signals for XPAR:EAPI:

  • 3-Year Book Growth Rate: -11.20%
  • GF Value™: €2.88 vs. price of €1.27 (55.8% below fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the XPAR:EAPI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Euroapi Business Description

Other Exchanges EAPIF:USA0EAP:UK940:Germany
Address 32 rue Alexandre Duma, Paris, FRA, 75011
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
59GF Score

Get the complete analysis for XPAR:EAPI

3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.27
Price
€2.88
GF Value